KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) Return on Sales (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Return on Sales data on record, last reported at 2.45% in Q4 2025.

  • For Q4 2025, Return on Sales fell 101.0% year-over-year to 2.45%; the TTM value through Dec 2025 reached 1.88%, down 111.0%, while the annual FY2025 figure was 1.88%, 111.0% down from the prior year.
  • Return on Sales reached 2.45% in Q4 2025 per AQST's latest filing, down from 1.21% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.72% in Q1 2023 and bottomed at 6.18% in Q2 2021.
  • Average Return on Sales over 5 years is 1.44%, with a median of 1.13% recorded in 2022.
  • Peak YoY movement for Return on Sales: soared 415bps in 2022, then tumbled -179bps in 2024.
  • A 5-year view of Return on Sales shows it stood at 2.61% in 2021, then skyrocketed by 56bps to 1.16% in 2022, then skyrocketed by 47bps to 0.61% in 2023, then plummeted by -134bps to 1.44% in 2024, then tumbled by -70bps to 2.45% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Sales were 2.45% in Q4 2025, 1.21% in Q3 2025, and 1.35% in Q2 2025.